The funding agency aims to cap “indirect costs” in biomedical research grants. But this behind-the-scenes work is crucial to making research happen.

Balance sheet, already traditionally a strong element in the EVS finances, continues to improve. 2024 ends with a net cash position of EUR 74.9 million combined with low debt level (of which EUR 12.3 ...

EVS reports 2024 results EVS Achieves Record Revenue for Fourth Consecutive Year in 2024, Celebrating 30 Years of Success Liège, Belgium | February 18, 2025 2024 marks a significant milestone ...

Anglo American agrees sale of nickel business for up to $500 million Anglo American plc (‘Anglo American’) announces that it has entered into a definitive agreement to sell its nickel business to MMG ...